Cialis by Eli Lilly receives Orphan Drug Designation from FDA for the treatment of...

Cialis (tadalafil), marketed by Eli Lilly, a global pharmaceutical company headquartered in Indianapolis, IN received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of Duchenne muscular...

Thar Pharmaceuticals received Orphan Drug Designation for its ZLM for treatment of complex regional...

Thar Pharmaceuticals received Orphan Drug Designation from the FDA for its zoledronate D,L-lysine monohydrate (ZLM) for the treatment of complex regional pain syndrome (CRPS).  CRPS is a rare form of chronic...

FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma

The U.S. FDA today approved Genetech’s Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be...

U.S. FDA Ganted RGX-104 two Orphan Drug Designations for the Treatment of Ovarian Cancer...

The U.S. FDA has granted RGX-104 two Orphan Drug Designations for the treatment of ovarian cancer and glioblastoma multiforme.  RGX-104 is an orally bioavailable small molecule LXR-agonist under development by Rgenix,...

US FDA grants breakthrough therapy designation for investigational Bcl-2 inhibitor venetoclax in 17p deletion...

The U.S. Food and Drug Administration has granted venetoclax (RG7601, GDC-0199/ABT-199) Breakthrough Therapy Designation for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...